Progressive supranuclear palsy is a rare degenerative neurological disorder that affects movement, control of walking and balance, speech, swallowing, vision, mood and behavior, and thinking. The condition is caused by the gradual damage of brain cells. The neuropathological hallmark of PSP is a biochemical alteration in the tau protein, which results in a neurodegeneration and gliosis in the basal ganglia, brainstem, prefrontal cortex and cerebellum.
DelveInsight’s, “Progressive Supranuclear Palsy Pipeline Insight, 2021” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Progressive Supranuclear Palsy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Some of Progressive supranuclear palsy Companies are:
Request for free sample report: https://www.delveinsight.com/sample-request/progressive-supranuclear-palsy-pipeline-insight
DelveInsight’s Progressive supranuclear palsy report covers around 15+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Some of Progressive supranuclear palsy Therapies are:
Current Progressive supranuclear palsy Treatment Scenario and Progressive supranuclear palsy Emerging Therapies:
Table of Contents:
Introduction Executive Summary Progressive Supranuclear Palsy: Overview Pipeline Therapeutics • Comparative Analysis Therapeutic Assessment Progressive Supranuclear Palsy – DelveInsight’s Analytical Perspective In-depth Commercial Assessment • Progressive Supranuclear Palsy companies’ collaborations, Licensing, Acquisition -Deal Value Trends Progressive Supranuclear Palsy Collaboration Deals Late Stage Products (Phase III) • Comparative Analysis Drug name: Company name Drug profiles in the detailed report….. Mid Stage Products (Phase II) • Comparative Analysis RT001: Retrotope Drug profiles in the detailed report….. Early Stage Products (Phase I) • Comparative Analysis Bepranemab (UCB 0107): UCB Drug profiles in the detailed report….. Preclinical/Discovery Stage Products • Comparative Analysis MSUT2 programme: DTx Pharma Drug profiles in the detailed report….. Inactive Products • Comparative Analysis Progressive Supranuclear Palsy Key Companies Progressive Supranuclear Palsy Key Products Progressive Supranuclear Palsy- Unmet Needs Progressive Supranuclear Palsy- Market Drivers and Barriers Progressive Supranuclear Palsy- Future Perspectives and Conclusion Progressive Supranuclear Palsy Analyst Views Progressive Supranuclear Palsy Key Companies Appendix
Request for Detailed TOC: https://www.delveinsight.com/sample-request/progressive-supranuclear-palsy-pipeline-insight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/progressive-supranuclear-palsy-pipeline-insight